These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

830 related articles for article (PubMed ID: 23592805)

  • 1. Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging.
    Choi YJ; Kim HS; Jahng GH; Kim SJ; Suh DC
    Acta Radiol; 2013 May; 54(4):448-54. PubMed ID: 23592805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.
    Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB
    BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assesment of perfusion in glial tumors with arterial spin labeling; comparison with dynamic susceptibility contrast method.
    Cebeci H; Aydin O; Ozturk-Isik E; Gumus C; Inecikli F; Bekar A; Kocaeli H; Hakyemez B
    Eur J Radiol; 2014 Oct; 83(10):1914-9. PubMed ID: 25087109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiation of progressive disease from pseudoprogression using 3D PCASL and DSC perfusion MRI in patients with glioblastoma.
    Manning P; Daghighi S; Rajaratnam MK; Parthiban S; Bahrami N; Dale AM; Bolar D; Piccioni DE; McDonald CR; Farid N
    J Neurooncol; 2020 May; 147(3):681-690. PubMed ID: 32239431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regional and voxel-wise comparisons of blood flow measurements between dynamic susceptibility contrast magnetic resonance imaging (DSC-MRI) and arterial spin labeling (ASL) in brain tumors.
    White CM; Pope WB; Zaw T; Qiao J; Naeini KM; Lai A; Nghiemphu PL; Wang JJ; Cloughesy TF; Ellingson BM
    J Neuroimaging; 2014; 24(1):23-30. PubMed ID: 22672084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Percent change of perfusion skewness and kurtosis: a potential imaging biomarker for early treatment response in patients with newly diagnosed glioblastomas.
    Baek HJ; Kim HS; Kim N; Choi YJ; Kim YJ
    Radiology; 2012 Sep; 264(3):834-43. PubMed ID: 22771885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study of pulsed-continuous arterial spin labeling and dynamic susceptibility contrast imaging by histogram analysis in evaluation of glial tumors.
    Arisawa A; Watanabe Y; Tanaka H; Takahashi H; Matsuo C; Fujiwara T; Fujiwara M; Fujimoto Y; Tomiyama N
    Neuroradiology; 2018 Jun; 60(6):599-608. PubMed ID: 29705876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor recurrence versus treatment effects in glioma: A comparative study of three dimensional pseudo-continuous arterial spin labeling and dynamic susceptibility contrast imaging.
    Xu Q; Liu Q; Ge H; Ge X; Wu J; Qu J; Xu K
    Medicine (Baltimore); 2017 Dec; 96(50):e9332. PubMed ID: 29390403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiation between progression and pseudoprogresion by arterial spin labeling MRI in patients with glioblastoma multiforme.
    Jovanovic M; Radenkovic S; Stosic-Opincal T; Lavrnic S; Gavrilovic S; Lazovic-Popovic B; Soldatovic I; Maksimovic R
    J BUON; 2017; 22(4):1061-1067. PubMed ID: 28952228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging.
    Chu HH; Choi SH; Ryoo I; Kim SC; Yeom JA; Shin H; Jung SC; Lee AL; Yoon TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH
    Radiology; 2013 Dec; 269(3):831-40. PubMed ID: 23771912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma.
    Thomas AA; Arevalo-Perez J; Kaley T; Lyo J; Peck KK; Shi W; Zhang Z; Young RJ
    J Neurooncol; 2015 Oct; 125(1):183-90. PubMed ID: 26275367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of three different MR perfusion techniques and MR spectroscopy for multiparametric assessment in distinguishing recurrent high-grade gliomas from stable disease.
    Seeger A; Braun C; Skardelly M; Paulsen F; Schittenhelm J; Ernemann U; Bisdas S
    Acad Radiol; 2013 Dec; 20(12):1557-65. PubMed ID: 24200483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perfusion MR imaging of enhancing brain tumors: Comparison of arterial spin labeling technique with dynamic susceptibility contrast technique.
    Soni N; Dhanota DPS; Kumar S; Jaiswal AK; Srivastava AK
    Neurol India; 2017; 65(5):1046-1052. PubMed ID: 28879895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of arterial transit time delays on the differentiation between tumor progression and pseudoprogression in glioblastoma by arterial spin labeling magnetic resonance imaging.
    van Dorth D; Jiang FY; Schmitz-Abecassis B; Croese RJI; Taphoorn MJB; Smits M; Koekkoek JAF; Dirven L; de Bresser J; van Osch MJP
    NMR Biomed; 2024 Apr; ():e5166. PubMed ID: 38654579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of pseudoprogression in patients with glioblastomas using the initial and final area under the curves ratio derived from dynamic contrast-enhanced T1-weighted perfusion MR imaging.
    Suh CH; Kim HS; Choi YJ; Kim N; Kim SJ
    AJNR Am J Neuroradiol; 2013 Dec; 34(12):2278-86. PubMed ID: 23828115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pediatric astrocytic tumor grading: comparison between arterial spin labeling and dynamic susceptibility contrast MRI perfusion.
    Morana G; Tortora D; Staglianò S; Nozza P; Mascelli S; Severino M; Piatelli G; Consales A; Lequin M; Garrè ML; Rossi A
    Neuroradiology; 2018 Apr; 60(4):437-446. PubMed ID: 29453753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perfusion MRI (dynamic susceptibility contrast imaging) with different measurement approaches for the evaluation of blood flow and blood volume in human gliomas.
    Thomsen H; Steffensen E; Larsson EM
    Acta Radiol; 2012 Feb; 53(1):95-101. PubMed ID: 22114021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uninterpretable Dynamic Susceptibility Contrast-Enhanced Perfusion MR Images in Patients with Post-Treatment Glioblastomas: Cross-Validation of Alternative Imaging Options.
    Heo YJ; Kim HS; Park JE; Choi CG; Kim SJ
    PLoS One; 2015; 10(8):e0136380. PubMed ID: 26296086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glioblastoma treated with concurrent radiation therapy and temozolomide chemotherapy: differentiation of true progression from pseudoprogression with quantitative dynamic contrast-enhanced MR imaging.
    Yun TJ; Park CK; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH; Choi SH
    Radiology; 2015 Mar; 274(3):830-40. PubMed ID: 25333475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of three-dimensional pseudo-continuous arterial spin labeling perfusion imaging with gradient-echo and spin-echo dynamic susceptibility contrast MRI.
    Wong AM; Yan FX; Liu HL
    J Magn Reson Imaging; 2014 Feb; 39(2):427-33. PubMed ID: 23677620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.